Show simple item record

dc.contributor.authorGainza Luzea, Garazies
dc.contributor.authorAguirre, José Javieres
dc.contributor.authorPedraz Muñoz, José Luis ORCIDes
dc.contributor.authorHernández Martín, Rosa María ORCIDes
dc.contributor.authorIgartua Olaechea, Manuela ORCIDes
dc.date.accessioned2014-09-10T11:26:23Zes
dc.date.accessioned2014-10-08T08:20:04Z
dc.date.available2014-09-10T11:26:23Zes
dc.date.available2014-10-08T08:20:04Z
dc.date.issued2013es
dc.identifier.citationEuropean Journal of Pharmaceutical Sciences (2013)es
dc.identifier.issn0928-0987es
dc.identifier.urihttp://hdl.handle.net/10810/13317es
dc.description.abstract[EN] Diabetic foot ulcers (DFUs) represent a major clinical challenge in the ageing population. To address this problem, rhEGF-loaded Poly-Lactic-co-Glycolic-Acid (PLGA)-Alginate microspheres (MS) were prepared by a modified w/o/w-doubleemulsion/ solvent evaporation method. Different formulations were evaluated with the aim of optimising MSs properties by adding NaCl to the surfactant solution and/or the solvent removal phase and adding alginate as a second polymer. The characterization of the developed MS showed that alginate incorporation increased the encapsulation efficiency (EE) and NaCl besides increasing the EE also became the particle surface smooth and regular. Once the MS were optimised, the target loading of rhEGF was increased to 1% (PLGA-Alginate MS), and particles were sterilised by gamma radiation to provide the correct dosage for in vivo studies. In vitro cell culture assays demonstrated that neither the microencapsulation nor the sterilisation process affected rhEGF bioactivity or rhEGF wound contraction. Finally, the MS were evaluated in vivo for treatment of the full-thickness wound model in diabetised Wistar rats. rhEGF MS treated animals showed a statistically significant decrease of the wound area by days 7 and 11, a complete re-epithelisation by day 11 and an earlier resolution of the inflammatory process. Overall, these findings demonstrate the promising potential of rhEGF-loaded MS (PLGA-Alginate MS) to promote faster and more effective wound healing, and suggest its possible application in DFU treatment.en
dc.language.isoengen
dc.publisherElsevieres
dc.rightsinfo:eu-repo/semantics/openAccessen
dc.subjectpoly-lactic-co-glycolic-acid (PLGA)en
dc.subjectalginateen
dc.subjectrecombinant human epidermal growth factor (rhEGF)en
dc.subjectwound healingen
dc.subjecttissue engineeringen
dc.titlerhegf-Loaded Plga-Alginate Microspheres Enhance The Healing Of Full-Thickness Excisional Wounds In Diabetised Wistar Ratsen
dc.typeinfo:eu-repo/semantics/articleen
dc.rights.holder© Elsevieren
dc.identifier.doihttp://dx.doi.org/10.1016/j.ejps.2013.07.003en
dc.departamentoesFarmacia y ciencias de los alimentoses_ES
dc.departamentoeuFarmazia eta elikagaien zientziakes_ES
dc.subject.categoriaPHARMACEUTICAL SCIENCE


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record